Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the final ceremony, exposed one of the key conference sponsors, ...

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

HVTN 705 vaccine study passes its “go” criteria: due to start this autumn A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, ...